JHIU
PDLI

Janus Henderson Investors US’s PDL BioPharma, Inc. PDLI Stock Holding History

Janus Henderson Investors US’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$25K Sell
10,896
-127
-1% -$281 ﹤0.01% 1150
2016
Q4 		$23K Buy
+11,023
New +$30.8K ﹤0.01% 1200

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Janus Henderson Investors US's PDLI Position: Q1 2017 in Review

Janus Henderson Investors US reduced its PDL BioPharma, Inc. (PDLI) stake by 1.2% in Q1 2017, selling an estimated $281 and leaving 10,896 shares worth $25K. The position accounts for ﹤0.01% of the portfolio, ranked #1150.

Janus Henderson Investors US first reported a position in PDLI in Q4 2016 and has held it in 2 quarters since. 174 funds tracked by Wall St. Rank hold PDLI as of Q1 2017.

  • Janus Henderson Investors US held 10,896 shares of PDL BioPharma, Inc. worth $25K as of Q1 2017.
  • Janus Henderson Investors US sold 127 PDL BioPharma, Inc. shares in Q1 2017, an estimated $281.
  • PDL BioPharma, Inc. made up ﹤0.01% of Janus Henderson Investors US's portfolio in Q1 2017, its #1150 holding.
  • Janus Henderson Investors US first reported a position in PDL BioPharma, Inc. in Q4 2016 and has held it in 2 quarters since.
  • 174 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.